insights_auto
Sebab 688235 meningkat 2.50%?
Terokai Dengan Lebih Terperincichevron_right
688235:SHA
BeOne Medicines AG
CN¥245.99
arrow_upward
+2.50%(+6.00) 1H
15 Okt, 3:00:00 PTG GMT+8 · CNY
search
Semua simbol
| Simbol | Harga | Perubahan | % Perubahan |
|---|
insights_autoMenjana cerapan popular untuk 688235...
Buka
CN¥238.70
Tinggi
CN¥249.93
Rendah
CN¥237.84
Permodalan Pasaran
289.03B
Purata volum
2.82J
Volum
3.53J
Nisbah H/P
87.86
tgi 52 mgu
CN¥319.24
rdh 52 mgu
CN¥205.51
EPS
CN¥2.80
Bilangan pekerja
12K
Buka
CN¥238.70
Tinggi
CN¥249.93
Rendah
CN¥237.84
Permodalan Pasaran
289.03B
Purata volum
2.82J
Volum
3.53J
Nisbah H/P
87.86
tgi 52 mgu
CN¥319.24
rdh 52 mgu
CN¥205.51
EPS
CN¥2.80
Bilangan pekerja
12K
Cerita berita
Daripada sumber web dan rakan kongsi berita
MarketBeat
·
14 jam lalu
Sanders Morris Harris LLC Makes New Investment in BeOne Medicines Ltd. - Sponsored ADR $ONC
Simply Wall Street
·
20 jam lalu
BeOne Medicines (ONC) Stock Trades Above Fair Value Following Its 103% Run
Profil
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.
Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has locations on six continents, in over 45 countries. BeOne has a large presence in the Chinese market.
BeOne Medicines has developed several medicines, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November 2024, the company announced its intention to rebrand as BeOne Medicines. BeOne changed its stock ticker to ONC in January 2025 and redomiciled to Basel, Switzerland in May 2025. Wikipedia
Perihal BeOne Medicines AG
CEOJohn Vincent Oyler | John Vincent Oyler
Pekerja12K
Diasaskan28 Okt 2010
Ibu pejabat-
Sektor-
Laman webbeonemedicines.com